Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.

Journal article

Suramin is an antitrypanosomal agent with antineoplastic activity, but with serious systemic side effects. We administered Suramin intravesically to determine a concentration with low toxicity but with evidence of a pharmacodynamic effect, to recommend a dose level for phase II trials. This was an open-labelled, non-randomized dose-escalation phase I study. In all, 12 patients with a history of recurrent superficial bladder cancer were grouped into four dose levels (10-150 mg ml(-1) in 60 ml ...

Expand abstract

Authors: Ord, J; Streeter, E; Jones, A; Le Monnier, K; Cranston, D

• Publication status: Published
• Journal: British journal of cancer
• Volume: 92
• Issue: 12
• Pages: 2140-2147
• Publication date: 2005-06-01
• DOI: 10.1038/sj.bjc.6602650
• EISSN: 1532-1827
• ISSN: 0007-0920
• Language: English
• Keywords: Humans; Antineoplastic Agents; Proteinuria; Middle Aged; Treatment Outcome; Neoplasm Recurrence, Local; Suramin; Male; Vascular Endothelial Growth Factor A; Maximum Tolerated Dose; Aged; Urinary Bladder Neoplasms; Dose-Response Relationship, Drug; Administration, Intravesical; Female; Aged, 80 and over; Carcinoma, Transitional Cell